Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nifecardia SRFC vs Adalat OROS in Essential Hypertension
NCT00173667Phase 4Unknown
- Sponsor
- National Taiwan University Hospital
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of nifedipine in essential hypertension (2 arms), sponsored by National Taiwan University Hospital. Primary endpoints: Antihypertensive Efficacy at 8 weeks and Safety and Tolerability at 8 weeks. Status: unknown.
02
Drugs
nifedipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT00173667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00173667.